Tracers / [131I]iodine

[131I]iodine

Also written as [I-131]iodine; [I-131]Iodine
Radionuclide
I-131 t½ 11549 min
Modality
Therapy
Production route
Stage
Syntheses indexed
3

What it is

Compound class
Target / mechanism
Sodium iodide symporter (NIS)-mediated iodide uptake following gene transfer PMID 36458201
Clinical application
Glioblastoma (GBM) - NIS gene therapy with radioiodide (131I) for tumor treatment PMID 36458201
Theranostic pair

Regulatory status

FDA
EMA (centralised)
Other approvals
Brand names

Clinical use

Typical injected activity
Uptake time

Reported in the literature. Not a dosing recommendation.

Published syntheses

ModuleCassettePurificationYield %RCP %Precursor / supplierSource
Manual synthesisSPE36458201
2022 Mol Ther Oncolytics
Briefly, 18F− in H2O (starting activity 6 GBq), trapped on a preconditioned (first 0.9% NaCl [5 mL], then H2O [10 mL]) quaternary methyl ammonium (QMA) ion exchange column
9098hyaluronic acid (HA) microgels with radiolabeling functional groups42574923
2026 J Control Release
absorption-mediated rapid labeling of radioactive iodine-131 (131I) to uniform freeze-dried microgels — high radiolabeling efficiency (> 90% within 10 min)
10740654
2000 Cancer Biother Radiopharm

Need this precursor?We can point you to suppliers for [131I]iodine, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty.